(Q33539673)

27 July 2017

1 reference

title

Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? (English)

1 reference

ORCID Public Data File 2021

27 July 2017

1 reference

author name string

Ruckdeschel JC

1

1 reference

27 July 2017

Gridelli C

2

1 reference

27 July 2017

Perrone F

3

1 reference

27 July 2017

Monfardini S

4

1 reference

27 July 2017

Giaccone G

5

1 reference

27 July 2017

1 December 1998

1 reference

European Journal of Cancer

27 July 2017

1 reference

27 July 2017

34

1 reference

27 July 2017

1993-1999

1 reference

27 July 2017

13

1 reference

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900309-8

7 January 2021

10.1016/S0959-8049(98)00309-8

Identifiers

DOI

1 reference

27 July 2017

1 reference